Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Mitsunori Hino"'
Autor:
Takeru Kashiwada, Yosuke Tanaka, Toru Tanaka, Tetsuya Okano, Yoshinobu Saito, Masahiro Seike, Mitsunori Hino, Hiroshi Kimura, Akihiko Gemma
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background The data on bosentan were lacking for the treatment of exercise-induced elevation of pulmonary artery pressure (eePAP) or less severe PH in COPD. This study was conducted to investigate long-term efficacy and safety of bosentan fo
Externí odkaz:
https://doaj.org/article/4eec458e48824e8aad40b58239dfee83
Autor:
Rintaro Noro, Kunihiko Kobayashi, Jiro Usuki, Makiko Yomota, Masaru Nishitsuji, Tsuneo Shimokawa, Masahiro Ando, Mitsunori Hino, Koichi Hagiwara, Akihiko Miyanaga, Masahiro Seike, Kaoru Kubota, Akihiko Gemma, North East Japan Study group
Publikováno v:
Thoracic Cancer, Vol 11, Iss 7, Pp 1876-1884 (2020)
Background Pleurodesis is the standard of care for non‐small cell lung cancer (NSCLC) patients with symptomatic malignant pleural effusion (MPE). However, there is no standard management for MPE uncontrolled by pleurodesis. Most patients with unsuc
Externí odkaz:
https://doaj.org/article/e56715d689f44682919ff6c58a8821cc
Publikováno v:
Respiratory Medicine Case Reports, Vol 26, Iss , Pp 223-226 (2019)
One of the novel PD-1 antibodies/immune checkpoint inhibitors, nivolumab is reported to be associated with a wide range of immune-related adverse events (irAEs). We hereby report a case of isolated adrenocorticotropic hormone (ACTH) deficiency develo
Externí odkaz:
https://doaj.org/article/db75372e5d21425b870b3ee5bde90317
Publikováno v:
BMC Pulmonary Medicine, Vol 17, Iss 1, Pp 1-14 (2017)
Abstract Background No drugs have been approved for the treatment of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF), particularly those with idiopathic honeycomb lung. This study was conducted to investigat
Externí odkaz:
https://doaj.org/article/facd017edeb64bf483189521d9a16cb4
Publikováno v:
Respiratory Medicine Case Reports, Vol 21, Iss C, Pp 62-65 (2017)
A 72-year-old woman was admitted to our hospital and was diagnosed with interstitial pneumonia (IP) associated with amyopathic dermatomyositis (ADM). The patient experienced three acute IP exacerbations in the 7 years that followed, which were each t
Externí odkaz:
https://doaj.org/article/fac29ae39d2a419ea7d026c1a42a610a
Publikováno v:
Respiratory Medicine Case Reports, Vol 27, Iss , Pp - (2019)
We report a case of non–small-cell lung cancer (NSCLC) to small-cell lung cancer (SCLC) transformation after epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. The patient was a man who diagnosed with EGFR-mutant advan
Externí odkaz:
https://doaj.org/article/4792ed06476042ceb6b52bb98679ca1e
Publikováno v:
Respiratory Medicine Case Reports, Vol 14, Iss C, Pp 19-23 (2015)
Pulmonary hypertension is a poor prognostic factor in patients with interstitial lung disease. No established treatment exists for pulmonary hypertension secondary to interstitial pneumonia. We describe the case of an 81-year-old woman with idiopathi
Externí odkaz:
https://doaj.org/article/eaccf4518321492ba737d3dcca29cc32
Autor:
Namiko Taniuchi, Mitsunori Hino, Akiko Yoshikawa, Akihiko Miyanaga, Yosuke Tanaka, Masahiro Seike, Akihiko Gemma
Publikováno v:
Journal of Asthma. 60:769-783
Autor:
Kaoru Kubota, Masaru Nishitsuji, Masahiro Seike, Koichi Hagiwara, Masahiro Ando, Makiko Yomota, Akihiko Miyanaga, Mitsunori Hino, Tsuneo Shimokawa, Rintaro Noro, Akihiko Gemma, Jiro Usuki, Kunihiko Kobayashi
Publikováno v:
Thoracic Cancer. 11:1876-1884
Background Pleurodesis is the standard of care for non-small cell lung cancer (NSCLC) patients with symptomatic malignant pleural effusion (MPE). However, there is no standard management for MPE uncontrolled by pleurodesis. Most patients with unsucce
Autor:
Yoshinobu Saito, Masahiro Seike, Takeru Kashiwada, Akihiko Gemma, Mizuki Yuasa, Namiko Taniuchi, Yosuke Tanaka, Tohru Tanaka, Mitsunori Hino
Publikováno v:
Cureus
Background The role of inhaled corticosteroid (ICS) in chronic obstructive pulmonary disease (COPD) is unclear. Hence, this study aimed to evaluate the efficacy of ICS as an add-on to long-acting muscarinic antagonist (LAMA)/long-acting beta 2 agonis